Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
ALK – Financial calendar for the 2025 financial year 2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22 January 2025: Silent period 19...
Positive results advance peanut tablet to phase II development ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding and...
ACARIZAX® approved in Europe for treatment of young children ALK (ALKB:DC / OMX: ALK B) today announced that its European regulatory filing for ACARIZAX® (house dust mite sublingual allergy...
ALK’s pivotal phase 3 trial in children published in reputable scientific journal The reputable scientific journal, The Lancet Regional Health – Europe, has published robust results from ALK’s...
Nine-month interim report (Q3) 2024 (unaudited) Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin of 23% in Q3 Revenue growth was mainly driven by...
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) ALK (ALKB:DC / OMX: ALK B) today announced that it has entered...
Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024 ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first nine...
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff ALK (ALKB:DC / OMX: ALK B / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014...
Six-month interim report (Q2) 2024 Company release No. 16/2024 ALK delivers 21% organic revenue growth with an operating profit margin of 19% in Q2 (unaudited) Revenue growth was driven by a...
ALK upgrades its full-year revenue and earnings outlook ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect the current performance...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.6 | -2.81690140845 | 21.3 | 21.74 | 20.82 | 76 | 21.46370041 | DE |
| 4 | -1.06 | -4.87132352941 | 21.76 | 21.8 | 20.28 | 354 | 20.74106876 | DE |
| 12 | -1.62 | -7.25806451613 | 22.32 | 23.3 | 20.16 | 292 | 21.69278636 | DE |
| 26 | 0.04 | 0.193610842207 | 20.66 | 24.56 | 19.13 | 331 | 22.26436077 | DE |
| 52 | 0.02 | 0.0967117988395 | 20.68 | 24.56 | 19.05 | 344 | 21.80792524 | DE |
| 156 | 0.02 | 0.0967117988395 | 20.68 | 24.56 | 19.05 | 344 | 21.80792524 | DE |
| 260 | 0.02 | 0.0967117988395 | 20.68 | 24.56 | 19.05 | 344 | 21.80792524 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
